Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epidermal Growth Factor”

1,015 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,015 results

Large-scale testing (Phase 3)Study completedNCT03206151
What this trial is testing

CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Taizhou Mabtech Pharmaceutical Co.,Ltd 520
Early research (Phase 1)Study completedNCT01238237
What this trial is testing

Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA

Who this might be right for
Glioblastoma Multiforme (GBM)ANAPLASTIC ASTROCYTOMA (AOA)GBM+1 more
Northwell Health 15
Early research (Phase 1)Ended earlyNCT03816839
What this trial is testing

Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)

Who this might be right for
Breast Cancer
Sanofi 10
Large-scale testing (Phase 3)Looking for participantsNCT06989112
What this trial is testing

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Who this might be right for
Endometrial Cancer
AstraZeneca 600
Not applicableStudy completedNCT01389401
What this trial is testing

Salivary Epidermal Growth Factor (EGF) Concentration Before and After Treatment of Reflux Laryngitis

Who this might be right for
Gastroesophageal Reflux Disease (GERD)Chronic Laryngitis
Faculdade de Ciências Médicas da Santa Casa de São Paulo 36
Testing effectiveness (Phase 2)Study completedNCT01260181
What this trial is testing

Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 30
Testing effectiveness (Phase 2)Study completedNCT02917993
What this trial is testing

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Incyte Corporation 59
Early research (Phase 1)Study completedNCT01737008
What this trial is testing

Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck

Who this might be right for
Squamous Cell Carcinoma of the Head and Neck
University Health Network, Toronto 12
Testing effectiveness (Phase 2)Study completedNCT00589706
What this trial is testing

A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas

Who this might be right for
Gliomas
Drexel University College of Medicine 11
Not applicableStudy completedNCT06003114
What this trial is testing

Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs

Who this might be right for
Breast Cancer
Pfizer 472
Testing effectiveness (Phase 2)UnknownNCT03994393
What this trial is testing

Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.

Who this might be right for
EGFR Mutant Advanced Non Small Cell Lung Cancer
University of Sydney 100
Early research (Phase 1)WithdrawnNCT01941849
What this trial is testing

Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma

Who this might be right for
PhaeochromocytomaParaganglioma
University College, London
Early research (Phase 1)Looking for participantsNCT07063693
What this trial is testing

ABY-029 Glioma Trial

Who this might be right for
Intracranial Tumor
Dartmouth-Hitchcock Medical Center 33
Not applicableEnded earlyNCT02483416
What this trial is testing

Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 30
Early research (Phase 1)Study completedNCT00903734
What this trial is testing

An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

Who this might be right for
Advanced Cancers
M.D. Anderson Cancer Center 16
Early research (Phase 1)Study completedNCT00040781
What this trial is testing

Gefitinib in Treating Children With Refractory Solid Tumors

Who this might be right for
Unspecified Childhood Solid Tumor, Protocol Specific
National Cancer Institute (NCI) 45
Large-scale testing (Phase 3)Active Not RecruitingNCT05840211
What this trial is testing

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Who this might be right for
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast Cancer
Gilead Sciences 654
Testing effectiveness (Phase 2)Study completedNCT02049957
What this trial is testing

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Calithera Biosciences, Inc 118
Early research (Phase 1)Study completedNCT02476539
What this trial is testing

Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Tianjin Hemay Pharmaceutical Co., Ltd 28
Testing effectiveness (Phase 2)UnknownNCT01714908
What this trial is testing

Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21

Who this might be right for
Non-small Cell Lung Cancer
Jinming Yu 100
Load More Results